Nuvation Bio Inc.
- Open
- 5.41
- Day high
- 5.85
- Day low
- 5.34
- Prev close
- 5.64
- Volume
- 3.6M
- Mkt cap
- $2.0B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 6.3
- P/S
- 14.1
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$1.7M over the last 3 months (1 open-market buy, 5 sales)
- 🏛Institutions accumulating (13F)
Nuvation Bio Inc. (NUVB) is a Healthcare company listed on NYSE. The stock is up 152% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 5 sales (SEC Form 4).
Nuvation Bio Inc. (NUVB) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 4 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
NUVB earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 4, 2026 | $0.12 | $0.01 | -91.7% | $83M | +25.7% |
| Aug 7, 2025 | $-0.17 | $-0.17 | +0.0% | $5M | +33.4% |
| May 7, 2025 | $-0.16 | $-0.16 | +0.0% | $3M | +763.5% |
| Mar 6, 2025 | $-0.14 | $-0.15 | -7.1% | $6M | +585.3% |
| Feb 29, 2024 | $-0.10 | $-0.06 | +40.0% | $264000 | — |
| Nov 2, 2023 | $-0.10 | $-0.09 | +10.0% | — | — |
| Aug 3, 2023 | $-0.11 | $-0.09 | +18.2% | — | — |
| May 4, 2023 | $-0.09 | $-0.10 | -11.1% | — | — |
| Mar 15, 2023 | $-0.10 | $-0.10 | +0.0% | — | — |
| Nov 3, 2022 | $-0.14 | $-0.12 | +14.3% | — | — |
| Aug 4, 2022 | $-0.13 | $-0.16 | -23.1% | — | — |
| Feb 28, 2022 | $-0.12 | $-0.12 | +0.0% | — | — |
NUVB insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 17, 2026 | Sauvage Philippeofficer: Chief Financial Officer | Option | 39,999 | $2.17 |
| Jul 17, 2026 | Sauvage Philippeofficer: Chief Financial Officer | Option | 1 | $1.97 |
| Jun 24, 2026 | Sauvage Philippeofficer: Chief Financial Officer | Sell | 47,668 | $6.01 |
| Jun 24, 2026 | Markel Stacyofficer: CHIEF PEOPLE OFFICER | Option | 90,380 | $1.87 |
| Jun 24, 2026 | Markel Stacyofficer: CHIEF PEOPLE OFFICER | Option | 34,620 | $1.74 |
| Jun 24, 2026 | Markel Stacyofficer: CHIEF PEOPLE OFFICER | Sell | 125,000 | $6.03 |
| Jun 24, 2026 | Wentworth Kerryofficer: CHIEF REGULATORY OFFICER | Option | 63,000 | $2.93 |
| Jun 24, 2026 | Wentworth Kerryofficer: CHIEF REGULATORY OFFICER | Sell | 63,000 | $6.02 |
| Jun 24, 2026 | Sauvage Philippeofficer: Chief Financial Officer | Option | 47,668 | $2.17 |
| Jun 11, 2026 | Mashal Robertdirector | Buy | 25,000 | $4.73 |
| May 26, 2026 | FALBERG KATHRYN Edirector | Grant | 123,397 | $4.79 |
| May 26, 2026 | BLICKENSTAFF KIM Ddirector | Grant | 123,397 | $4.79 |
| May 26, 2026 | Bazemore Robert Bdirector | Grant | 123,397 | $4.79 |
| May 26, 2026 | Cui Xiangmindirector | Grant | 123,397 | $4.79 |
| May 26, 2026 | Cui Xiangmindirector | Grant | 76,923 | $5.91 |
Source: NUVB SEC Form 4 filings, latest Jul 17, 2026. For informational purposes only — not investment advice.
See the full NUVB insider & 13F page →Nuvation Bio Inc. company profile
Overview
Nuvation Bio Inc. (NASDAQ:NUVB) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in New York, New York. Originally incorporated as RePharmation Inc., the company changed its name to Nuvation Bio Inc. in April 2019 and went public in August 2020. The company focuses on developing innovative therapeutic candidates for oncology, with its lead asset taletrectinib approaching FDA approval with a PDUFA date of June 23, 2025.
Business
Nuvation Bio operates in the biotechnology sector, specifically focusing on developing small molecule drugs for cancer treatment. The company's approach centers on targeting specific molecular pathways that drive tumor growth and survival. The company's lead product candidate is taletrectinib, a small molecule inhibitor designed to target ROS1-positive non-small cell lung cancer. ROS1 is a genetic alteration found in approximately 1-2% of lung cancer patients, representing about 3,000 new patients annually in the United States. Taletrectinib has received breakthrough therapy designation from the FDA for both first-line and second-line treatment settings, meaning it addresses an unmet medical need with potentially significant clinical advantages over existing treatments. Beyond taletrectinib, Nuvation Bio has developed a diverse pipeline of oncology candidates. Safusidenib targets IDH1 mutant glioma, a type of brain cancer where the IDH1 enzyme is altered, leading to abnormal cell metabolism and tumor formation. NUV-1511 represents the company's first clinical candidate from their drug-drug conjugate (DDC) platform, which aims to deliver targeted cancer treatments more precisely to tumor cells while minimizing damage to healthy tissue. The company also develops NUV-868, a BET inhibitor that works by blocking proteins that control how genes are turned on and off in cancer cells, and NUV-569, a Wee1 kinase inhibitor that interferes with cancer cells' ability to repair DNA damage. Additionally, NUV-1182 is an adenosine receptor inhibitor designed to help the immune system better recognize and attack cancer cells. Revenue is currently minimal, primarily consisting of research collaboration payments and milestone payments, totaling approximately $7.9 million in fiscal year 2024. The company operates as a single segment focused entirely on oncology drug development.
Revenue model
Nuvation Bio's business model is typical of clinical-stage biopharmaceutical companies, where revenue generation occurs primarily through three mechanisms: product sales upon regulatory approval, licensing agreements with pharmaceutical partners, and milestone payments from collaborations. Currently, the company generates minimal revenue from research collaborations and milestone payments. The primary future revenue opportunity lies in commercializing taletrectinib, assuming FDA approval. The company has built a commercial infrastructure with 47 oncology account managers specifically targeting the ROS1-positive lung cancer market, which represents approximately 3,000 new patients annually in the United States. The company's revenue model will transition from development-stage to commercial-stage upon taletrectinib's potential approval. Revenue will come from direct product sales to hospitals, cancer centers, and specialty pharmacies. The target customer base consists of oncologists treating lung cancer patients, particularly those specializing in targeted therapies for rare genetic alterations. Several factors could significantly impact the company's margins and profitability. Positive factors include the breakthrough therapy designation which may facilitate faster regulatory approval and market penetration, the rare disease status of ROS1-positive lung cancer which typically commands premium pricing, and the strong clinical data showing 89% response rates and 46-month median progression-free survival. Negative factors include the small patient population limiting total addressable market, potential competition from other ROS1 inhibitors, manufacturing scale-up challenges, and the need for extensive physician education given the rarity of the condition. The company's current cash burn rate of approximately $130 million annually reflects the high costs associated with clinical trials, regulatory submissions, and building commercial capabilities. This burn rate is expected to continue until meaningful product revenues begin, making successful commercialization critical for long-term financial sustainability.
Competitive moat
Nuvation Bio's competitive moat is relatively narrow, typical of biotechnology companies developing treatments for rare cancer subtypes. The company's primary competitive advantage lies in taletrectinib's clinical differentiation, demonstrated through superior efficacy data including 89% confirmed overall response rate in treatment-naïve patients and 46-month median progression-free survival, which significantly exceeds current standard-of-care treatments. The breakthrough therapy designation provides a regulatory advantage and potential first-mover benefit in the ROS1-positive lung cancer market. Additionally, the company's experienced commercial team, drawn from successful oncology launches at Medivation and Maradis, provides execution capabilities that may accelerate market penetration. However, the moat faces several vulnerabilities. The small target market of approximately 3,000 annual patients limits the economic moat's depth, as competitors can meaningfully impact market share with relatively modest investments. Scientific competition remains significant, as other pharmaceutical companies are developing next-generation ROS1 inhibitors that could potentially offer superior efficacy or safety profiles. The company's drug-drug conjugate platform and pipeline diversity provide some protection against single-asset risk, but these remain in early development stages. Patent protection offers temporary exclusivity, but the specific patent landscape and duration for taletrectinib and other candidates would require detailed analysis to assess long-term competitive positioning. Overall, while Nuvation Bio has achieved meaningful clinical differentiation in a niche market, the moat is modest and depends heavily on successful execution of the taletrectinib launch and continued pipeline advancement to maintain competitive positioning in the rapidly evolving oncology landscape.
Risks & safety
Nuvation Bio presents a moderate margin of safety profile typical of late-stage biotechnology companies approaching commercialization. Liquidity and Solvency: • Strong cash position of $461.7 million plus additional $250 million from Sagard financing, providing substantial runway • Current ratio of 9.0x indicates excellent short-term liquidity • Minimal debt with debt-to-equity ratio of 0.027 • Annual cash burn of approximately $130 million suggests roughly 5+ years of operating runway at current burn rates Valuation Metrics: • Trading at 1.4x book value, reasonable for a company with significant cash reserves • Negative earnings multiples due to development-stage losses, typical for pre-revenue biotech • Enterprise value reflects the market's assessment of taletrectinib's commercial potential Other Considerations: • Binary risk profile with taletrectinib PDUFA date of June 23, 2025, representing significant catalyst • Diversified pipeline provides some protection against single-asset failure • Experienced management team with proven track record in oncology commercialization • Small target market limits downside risk but also caps upside potential
Recent development
Over the past few years, Nuvation Bio has executed a focused strategy centered on advancing taletrectinib toward commercialization while building a diversified oncology pipeline. The company's most significant achievement has been securing breakthrough therapy designation for taletrectinib in both first-line and second-line ROS1-positive lung cancer settings, with the FDA setting a PDUFA date of June 23, 2025. The company has demonstrated strong clinical execution with taletrectinib, achieving compelling efficacy data including 89% confirmed overall response rate in treatment-naïve patients, 46-month median progression-free survival, and 77% confirmed intracranial response rate. These results significantly exceed current standard-of-care treatments and have positioned taletrectinib as a potential best-in-class therapy. Strategically, Nuvation Bio has built commercial capabilities in anticipation of taletrectinib's approval, deploying 47 oncology account managers and leveraging an experienced launch team with proven success from previous oncology commercializations at Medivation and Maradis. The company has focused on early patient identification and physician education, recognizing that success in the rare ROS1-positive lung cancer market requires specialized expertise and targeted outreach. Pipeline development has progressed with safusidenib preparing for pivotal development in IDH1 mutant glioma, and NUV-1511 emerging as the first clinical candidate from the company's drug-drug conjugate platform. The company has also advanced NUV-868, a BD2-selective BET inhibitor with high selectivity profiles. These developments demonstrate Nuvation Bio's commitment to building a sustainable, diversified oncology portfolio beyond its lead asset. The company has strengthened its financial position through the Sagard financing arrangement, providing additional capital to support both the taletrectinib launch and continued pipeline development. This financial flexibility positions the company to execute on multiple strategic priorities simultaneously while maintaining adequate runway through the critical commercialization phase.
NUVB company profile · for informational purposes only — not investment advice.
Track NUVB with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free